TB Alliance

TB Alliance, formally The Global Alliance for TB Drug Development, is a nonprofit product development partnership focused on creating improved medicines for tuberculosis (TB), particularly drug-resistant TB and diseases affecting populations in low- and middle-income countries. The organization was conceived at a February 2000 meeting in Cape Town, South Africa, where representatives from academia, pharmaceutical companies, government agencies, nongovernmental organizations, and philanthropic institutions discussed the lack of progress in TB drug research. The meeting produced the Declaration of Cape Town, which called for a coordinated mechanism to reinvigorate the field and develop shorter, safer, more effective, and more accessible treatments. The organization was created to address a structural problem in global health innovation. Conventional TB treatment has historically required multiple medicines administered over many months, creating challenges for adherence, health-system monitoring, and completion of therapy. These challenges are especially serious in settings with limited clinical infrastructure and among people living with HIV. The emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) further increased the need for new drug classes and treatment combinations. Because TB is concentrated in poorer countries and medicines must be priced affordably, the commercial market alone has generally provided insufficient incentives for pharmaceutical companies to sustain a broad research pipeline. TB Alliance uses the product development partnership model to fill part of this gap. It coordinates public-sector, private-sector, academic, and philanthropic partners while retaining strategic oversight of drug-development programs. Laboratory studies, clinical trials, manufacturing, regulatory work, and other activities are commonly conducted through external institutions and contractors. This structure allows the organization to combine scientific capabilities without building a large internal infrastructure and is intended to reduce development costs and accelerate progress. A central feature of TB Alliance's approach is to consider access and affordability during development rather than after regulatory approval. Licensing arrangements can include provisions relating to pricing and availability, and the organization works with national and international partners to support registration, adoption, procurement, and distribution in countries where TB is prevalent. Its stated goal is not simply to bring medicines through clinical development, but to make resulting therapies practical for patients and health systems. The organization's most visible clinical and regulatory achievement has been its development of pretomanid. In 2019, the U.S. Food and Drug Administration accepted the drug's application for review and subsequently approved pretomanid for use in combination with bedaquiline and linezolid for certain adults with highly drug-resistant TB, including XDR-TB and MDR-TB that is treatment-intolerant or nonresponsive. The three-drug regimen became known as the BPaL regimen and represented an important expansion of options for patients with limited alternatives. Pretomanid's development also illustrated TB Alliance's partnership-based model, involving collaboration with external research and commercial organizations. TB Alliance is headquartered in New York City and has maintained a regional office in Pretoria, South Africa. Its work is supported by a diverse group of governmental agencies, foundations, and global-health funders, including the Bill & Melinda Gates Foundation, the United States Agency for International Development, the U.S. National Institute of Allergy and Infectious Diseases, the United Kingdom, Australia, Germany, Ireland, the Netherlands, and the GHIT Fund. The organization continues to focus on building a pipeline of novel TB medicines and combinations, with particular attention to shorter treatment durations, drug resistance, tolerability, interaction with HIV medicines, and equitable global access.

TB Alliance emerged from an international effort to restart tuberculosis drug innovation after decades in which the field had produced few major new treatment options. At a February 2000 meeting in Cape Town, South Africa, approximately 120 participants from research institutions, pharmaceutical companies, government agencies, nongovernmental organizations, and donor organizations examined the scientific and public-health consequences of the stagnant TB pipeline. The participants emphasized that existing therapy was lengthy and difficult to deliver, while drug resistance and the interaction between TB and HIV created additional clinical problems. Their discussions resulted in the Declaration of Cape Town, which set out a roadmap for developing faster-acting, novel, and affordable TB medicines and provided the basis for establishing the organization. The organization was initially known as the Global Alliance for TB Drug Development and later became widely identified as TB Alliance. It was established as a nonprofit product development partnership rather than as a conventional pharmaceutical company. Its operating model was designed to coordinate resources and expertise across sectors: public agencies and philanthropic funders could provide capital and public-health direction, academic groups could contribute discovery and translational science, and pharmaceutical or biotechnology partners could provide compounds, development capabilities, manufacturing expertise, and regulatory experience. TB Alliance would manage programs and partnerships while much of the technical work was carried out by external laboratories, clinical research organizations, and other contractors. Maria Freire became the organization's first president and chief executive officer in 2001. She led the organization through its formative period and remained in the role until 2008, when she left to become president of the Lasker Foundation. Melvin Spigelman subsequently became president and chief executive officer. Under this leadership structure, TB Alliance continued to build a portfolio intended to address both drug-sensitive and drug-resistant TB, while seeking to ensure that access considerations were included in agreements with development and commercialization partners. The organization was created against a difficult epidemiological and economic background. Standard TB therapy has traditionally required several drugs over six months or longer. Long treatment courses can contribute to incomplete adherence and place pressure on health systems that lack the capacity for frequent monitoring. When the causative bacteria become resistant to key first-line medicines, treatment may become substantially longer, more toxic, and more expensive. TB's concentration in countries with limited resources also means that potential commercial returns are often insufficient to support the full cost and risk of pharmaceutical research. TB Alliance therefore positioned itself as a mechanism for advancing candidates that might otherwise remain underdeveloped and for negotiating access provisions suited to endemic markets. The development of pretomanid became a defining chapter in the organization's history. Pretomanid was developed as part of a strategy to create new combination regimens for difficult-to-treat TB. In February 2019, its application was accepted for review by the U.S. Food and Drug Administration. In August 2019, the FDA approved pretomanid for use with bedaquiline and linezolid in certain adults with extensively drug-resistant TB and in patients with multidrug-resistant TB who were treatment-intolerant or nonresponsive. The regimen, commonly referred to as BPaL, provided a new option for patients with highly limited treatment choices and demonstrated the potential of a nonprofit partnership to bring a novel TB medicine through regulatory review. TB Alliance's work extends beyond discovery and approval. The organization has sought to support registration, procurement, adoption, and delivery by working with governments, international health organizations, donors, manufacturers, and local healthcare systems. Its licensing philosophy includes attention to affordable pricing and availability in countries where TB is endemic. The organization has also maintained an international footprint, with headquarters in New York City and a regional office in Pretoria, reflecting its origins in South Africa and its focus on global rather than purely national health needs. Funding has come from a mix of government agencies, research institutions, foundations, and global-health financing organizations. Identified supporters include the Australian Department of Foreign Affairs and Trade, the Bill & Melinda Gates Foundation, Germany's Federal Ministry of Education and Research through KfW, the GHIT Fund, the Indonesia Health Fund, Irish Aid, the United Kingdom's Medical Research Council, the U.S. National Institute of Allergy and Infectious Diseases, the Netherlands Ministry of Foreign Affairs, the former UK Department for International Development, the UK Department of Health, and USAID. This diversified support reflects the organization's role as a public-interest drug-development platform rather than a listed commercial brand.

• 2019

  Pretomanid application accepted for FDA review

  [1]TB Allianceen.wikipedia.org

  The U.S. FDA accepted TB Alliance's application for review of pretomanid, a novel medicine for difficult-to-treat TB.

• 2019

  Pretomanid receives U.S. FDA approval

  [1]TB Allianceen.wikipedia.org

  Pretomanid was approved for use with bedaquiline and linezolid in specified cases of XDR-TB and treatment-intolerant or nonresponsive MDR-TB.

• 2008

  Leadership transitions to Melvin Spigelman

  [1]TB Allianceen.wikipedia.org

  Freire left TB Alliance to lead the Lasker Foundation, and Melvin Spigelman became president and chief executive officer.

• 2001

  Maria Freire becomes first chief executive

  [1]TB Allianceen.wikipedia.org

  Maria Freire was appointed the organization's first president and chief executive officer.

• 2000

  Declaration of Cape Town establishes the basis for TB Alliance

  [1]TB Allianceen.wikipedia.org

  An international meeting in Cape Town brought together around 120 representatives who called for a coordinated effort to develop shorter, newer, and more affordable tuberculosis treatments.

A nonprofit global-health drug developer and product development partnership focused on tuberculosis medicines for underserved patients, with affordability, shorter treatment, resistance management, and global access built into its development and licensing strategy.

• Tuberculosis medicine · 2019

  Pretomanid

  Pretomanid is a nitroimidazole tuberculosis medicine developed through TB Alliance's product-development partnership model. It is used as part of a combination regimen rather than as a standalone treatment. In 2019, the U.S. FDA approved it with bedaquiline and linezolid for certain adults with extensively drug-resistant TB and for some patients with multidrug-resistant TB who were treatment-intolerant or nonresponsive. Its development addressed the need for new medicines active against forms of TB with few remaining treatment options.

• Combination tuberculosis treatment · 2019

  BPaL regimen

  BPaL is a three-drug regimen consisting of bedaquiline, pretomanid, and linezolid. TB Alliance helped develop and advance the pretomanid component and the regimen's clinical and regulatory pathway. It was designed for certain highly drug-resistant or otherwise difficult-to-treat TB cases and represented a shorter, all-oral treatment approach compared with many older regimens, subject to applicable clinical guidance and patient eligibility.

• 2019

  Advance pretomanid as part of the BPaL regimenProduct launch

  Background

  Patients with XDR-TB and difficult-to-treat MDR-TB had limited therapeutic options and often faced lengthy or poorly tolerated treatment.

  Action taken

  TB Alliance submitted pretomanid for U.S. regulatory review and advanced its use with bedaquiline and linezolid.

  Aftermath

  The FDA approved pretomanid in 2019 for specified patients, making the BPaL combination a new option for certain highly drug-resistant TB cases.

  Source

• 2000

  Adopt a nonprofit product development partnership modelStrategy

  Background

  TB drug research had experienced prolonged underinvestment, while long treatment courses, drug resistance, and limited commercial returns created an unmet global-health need.

  Action taken

  TB Alliance was organized to coordinate governments, donors, academia, nongovernmental organizations, and industry around externally conducted discovery and clinical-development programs.

  Aftermath

  The model enabled TB Alliance to build a broad development pipeline while linking drug development to affordability and access objectives.

  Source

• 2019

  TB Alliance submits pretomanid application for U.S. review[1]TB Allianceen.wikipedia.org

  Product launch

  TB Alliance's application for pretomanid, a novel tuberculosis medicine, was accepted for review by the U.S. Food and Drug Administration.

• 2019

  FDA approves pretomanid for certain drug-resistant tuberculosis cases[1]TB Allianceen.wikipedia.org

  Product launch · Regulation

  The U.S. Food and Drug Administration approved pretomanid for use with bedaquiline and linezolid in adults with certain forms of highly drug-resistant or otherwise difficult-to-treat tuberculosis.

1. 1TB Allianceen.wikipedia.org
2. 2TB Alliance official websitetballiance.org